Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy

被引:83
作者
Hogg, RS
Rhone, SA
Yip, B
Sherlock, C
Conway, B
Schechter, MT
O'Shaughnessy, MV
Montaner, JSG
机构
[1] Univ British Columbia, St Pauls Hosp, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Pathol, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Fac Med, Dept Hlth Care & Epidemiol, Vancouver, BC V5Z 1M9, Canada
[4] Univ British Columbia, Virol Lab, Vancouver, BC V5Z 1M9, Canada
[5] Univ British Columbia, Fac Med, Dept Med, Vancouver, BC V5Z 1M9, Canada
关键词
zidovudine; didanosine; zalcitabine; lamivudine; stavudine; protease inhibitors; antiretroviral therapy; population-based cohort;
D O I
10.1097/00002030-199803000-00005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To study the antiviral effect and predictors of response to two-and three-drug regimens amongst antiretroviral-naive individuals using an intent-to-treat analysis. Main outcome measure: Suppression of plasma viral load to <500 copies/ml. Patients: A total of 420 (264 double drug, 156 triple drug) individuals in a province-wide treatment programme were studied. Results: A decrease in plasma viral load to <500 copies/ml was documented in 197 (47%) subjects. This was independently associated with a lower baseline plasma viral load (odds ratio, 3.67; 95% confidence interval, 2.13-6.30) and initiation onto a three-drug regimen (odds ratio, 3.86; 95% confidence interval, 2.24-6.66). Median plasma viral load failed to reach <500 copies/ml and in fact rebounded in the two-drug group. In contrast, 91 (58%) subjects receiving three drugs reached <500 copies/ml during the study period. Conclusion: These results support the use of powerful triple drug regimens as initial therapy in HIV-infected individuals.
引用
收藏
页码:279 / 284
页数:6
相关论文
共 22 条
  • [1] Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
  • [2] *BC CTR EXC HIV AI, 1996, THER GUID TREATM HIV
  • [3] Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24): : 1962 - 1969
  • [4] Antiretroviral therapy for HIV infection in 1996 - Recommendations of an international panel
    Carpenter, CCJ
    Fischl, MA
    Hammer, SM
    Hirsch, MS
    Jacobsen, DM
    Katzenstein, DA
    Montaner, JSG
    Richman, DD
    Saag, MS
    Schooley, RT
    Thompson, MA
    Vella, S
    Yeni, PG
    Volberding, PA
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (02): : 146 - 154
  • [5] *CDC, 1987, JAMA-J AM MED ASSOC, V258, P1143
  • [6] Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
    Collier, AC
    Coombs, RW
    Schoenfeld, DA
    Bassett, RL
    Timpone, J
    Baruch, A
    Jones, M
    Facey, K
    Whitacre, C
    McAuliffe, VJ
    Friedman, HM
    Merigan, TC
    Reichman, RC
    Hooper, C
    Corey, L
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (16) : 1011 - 1017
  • [7] Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3
  • [8] British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals
    Gazzard, BG
    Moyle, GJ
    Weber, J
    Johnson, M
    Bingham, JS
    Brettle, R
    Churchill, D
    Fisher, M
    Griffin, G
    Jefferies, D
    King, E
    Gormer, R
    Lee, C
    Pozniak, A
    Smith, JR
    TudorWilliams, G
    Williams, I
    [J]. LANCET, 1997, 349 (9058) : 1086 - 1092
  • [9] Survival in HIV-infected patients who have received zidovudine: Comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy
    Graham, NMH
    Hoover, DR
    Park, LP
    Stein, DS
    Phair, JP
    Mellors, JW
    Detels, R
    Saah, AJ
    Taylor, E
    Margolick, JB
    Markham, R
    McArthur, J
    Farzadegan, H
    Armenian, H
    Chmiel, JS
    Cohen, B
    Wesch, J
    Wolinsky, S
    Visscher, BR
    Fahey, JL
    Giorgi, JV
    Dudley, J
    Lee, M
    Nishanian, P
    Rinaldo, CR
    Kingsley, LA
    Kingsley, A
    Mellors, J
    Winkelstein, A
    Munoz, A
    Park, L
    Gange, S
    Nelson, K
    Jacobson, LP
    Su, S
    [J]. ANNALS OF INTERNAL MEDICINE, 1996, 124 (12) : 1031 - 1038
  • [10] Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
    Gulick, RM
    Mellors, JW
    Havlir, D
    Eron, JJ
    Gonzalez, C
    McMahon, D
    Richman, DD
    Valentine, FT
    Jonas, L
    Meibohm, A
    Emini, EA
    Chodakewitz, JA
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (11) : 734 - 739